Radius Health (RDUS) Says Positive Abaloparatide Phase 3 Data Published in JBMR
- Top 10 News for 9/19 - 9/23: Twitter on the Auction Block; Allergan Bolsters NASH Effort; Microsoft Returns Value
- Wall Street falls as energy lags; shares post gains on week
- Rumored Forever, Twitter (TWTR) May Have Finally Put the 'For Sale' Sign Up
- Facebook (FB) Shares Under Pressure on Reports Video Ad Metrics Were Artificially Inflated
- Brookfield Infrastructure (BIP)-Led Consortium to Take Controlling Stake in Petrobras' (PBR) NTS for $5.2B
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Radius Health, Inc. (Nasdaq: RDUS) announced that additional positive results from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial were published in the Journal of Bone and Mineral Research (JBMR).
In the article “Effects of Abaloparatide-SC on Fracture and Bone Mineral Density in Subgroups of Postmenopausal Women with Osteoporosis and Varying Baseline Risk Factors” JBMR 2016 Sept 9 [Epub ahead of print] patients in the ACTIVE trial were stratified into prespecified subgroups of baseline risk factors, inclusive of BMD, prior fracture history and age, to determine the consistency of the response for abaloparatide-SC versus placebo. http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2991/epdf
“Results from the Phase 3 ACTIVE trial show that abaloparatide-SC may provide substantial benefit for a broad range of postmenopausal women with osteoporosis irrespective of their baseline risk factors, including age and prior fracture history,” said Dr. Felicia Cosman, M.D., osteoporosis specialist and Medical Director of the Clinical Research Center at Helen Hayes Hospital, Senior Clinical Director of the National Osteoporosis Foundation, Professor of Medicine at Columbia University, consultant to Radius and lead author of the paper. “These data are important for the large number of postmenopausal women who may be at risk of a fracture and show that anabolic therapy could provide more consistent, potent and early benefits and may be the most efficient way for these patients to achieve ultimate bone mineral density goals.”
“We are pleased to have these findings published in JBMR, as well as the opportunity to present additional scientific information about abaloparatide-SC as part of the American Society of Bone and Mineral Research 2016 Annual Meeting,” said Dr. Lorraine A. Fitzpatrick, Chief Medical Officer of Radius. “Approximately two million osteoporotic fractures occur annually in the U.S., which create physical and psychological burdens for those affected by diminishing their independence and quality of life. Radius Health is committed to pursuing new therapeutic options which have the potential to improve outcomes for these patients.”
Abaloparatide is an investigational treatment for postmenopausal women with osteoporosis and its safety and efficacy have not been established. A Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of patients with postmenopausal osteoporosis was validated and is currently undergoing regulatory review by the European Medicines Agency (EMA), and a New Drug Application (NDA) for abaloparatide is currently under review by the U.S. Food & Drug Administration (FDA).
About Postmenopausal Osteoporosis
Osteoporosis is a silent disease, often displaying no signs or symptoms until a fracture occurs, leaving a majority of patients undiagnosed and undertreated. Osteoporotic fractures create a significant healthcare burden, and represent a significant unmet medical need. An estimated two million osteoporotic fractures occur annually in the U.S., and this number is projected to grow to three million by 2025.
The National Osteoporosis Foundation (NOF) has estimated that 10 million people in the U.S., composed of eight million women and two million men, already have osteoporosis, and another approximately 44 million people have low bone mass placing them at increased risk for osteoporosis.
The debilitating effects of osteoporosis have substantial costs. When left untreated, osteoporosis leads to fractures which can have both physical and emotional consequences on a patient including pain and disability, inability to fully perform routine work or daily activities, and in some cases, result in death.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alliant Energy (LNT) CFO Tom Hanson to Retire
- UPS (UPS), CyPhy Begin Testing Urgent Commercial Delivery-Focused UAVs
- Janssen Announces Submission of Sirukumab BLA to FDA as RA Treatment
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!